window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 3, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oncology

  • Clinical Development,Drug discovery,Oncology,Research & Development

    FoRx Therapeutics presents preclinical data on PARG inhibitor FORX-428 at ACS Spring 2026

    FoRx Therapeutics presents preclinical data on FORX-428, a PARG inhibitor [...]

    March 27, 2026
  • Biotech,Cell & Gene Therapy,Drug Development,Oncology

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    February 24, 2026
  • Clinical Development,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Regulatory Affairs

    Fennec presents real world data on Pedmark use in head and neck cancer

    Fennec Pharmaceuticals has presented real world data supporting the integration [...]

    February 24, 2026
  • Clinical Development,Clinical Trials,Immunology,Oncology,Pharmaceuticals and therapeutics

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    January 26, 2026
  • Healthcare leadership,Movers & Shakers,Pharmaceuticals and therapeutics

    Ahmed Moussa appointed country lead for Sanofi UK & Ireland

    Sanofi has appointed Ahmed Moussa as its new country lead [...]

    January 26, 2026
  • Central Nervous System,Clinical Development,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Regulatory Affairs

    Accord Healthcare disappointed as people with ES-SCLC in Scotland denied access to serplulimab

    Patients in Scotland living with extensive-stage small cell lung cancer [...]

    January 23, 2026
  • Biotech,CDMOs & Manufacturing,Clinical Development,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035

    Syngene International has extended its strategic collaboration with Bristol Myers [...]

    January 19, 2026
  • Artificial Intelligence,Biotech,Clinical Development,Clinical studies,Drug Development,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Immunai partners with Bristol Myers Squibb to apply immune system AI in clinical development

    Artificial Intelligence, Biotech, Clinical Development, Clinical studies, Drug Development, Partnerships [...]

    January 16, 2026
  • Biotech,Clinical Development,Clinical studies,Clinical Trials,Healthcare leadership,Movers & Shakers,Rare Diseases

    Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth

    Veristat, a global clinical research organization (CRO) and consultancy specializing [...]

    January 15, 2026
  • Biologics & Biosimilars,Biotech,Clinical Development,Clinical Trials,Drug Development,Oncology,Pharmaceuticals and therapeutics,Research & Development

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    January 13, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Strategies to extend ketamine antidepressant effects identified in new study
    Categories: Central Nervous System, Mental health, Neurosciences, Research & Development
  • Bullfrog AI signs commercial agreement with top 5 global pharma company to identify novel target in major depressive disorder
    Categories: Artificial Intelligence, Digital Health, Mental health, Neurosciences, Research & Development
  • Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes
    Categories: Biotech, Drug Delivery & Formulation, Drug Development, Partnerships & Funding, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top